X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Wockhardt with Piramal Healthcare - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

WOCKHARDT LTD. vs PIRAMAL ENTERPRISES - Comparison Results

WOCKHARDT LTD.    Change

Wockhardt is one of the leading domestic pharmaceutical companies with strong presence in the lifestyle segment and a growing focus on biotechnology. While the company made a string of acquisitions in the past namely 'Esparma GmbH' in Germany, 'Pinew... More

PIRAMAL ENTERPRISES 
   Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    WOCKHARDT LTD. PIRAMAL ENTERPRISES WOCKHARDT LTD./
PIRAMAL ENTERPRISES
 
P/E (TTM) x -15.9 36.6 - View Chart
P/BV x 2.6 3.0 85.4% View Chart
Dividend Yield % 1.3 0.8 158.6%  

Financials

 WOCKHARDT LTD.   PIRAMAL ENTERPRISES
EQUITY SHARE DATA
    WOCKHARDT LTD.
Mar-17
PIRAMAL ENTERPRISES
Mar-17
WOCKHARDT LTD./
PIRAMAL ENTERPRISES
5-Yr Chart
Click to enlarge
High Rs1,1292,095 53.9%   
Low Rs6271,025 61.2%   
Sales per share (Unadj.) Rs363.1492.8 73.7%  
Earnings per share (Unadj.) Rs-20.472.6 -28.2%  
Cash flow per share (Unadj.) Rs-7.094.7 -7.4%  
Dividends per share (Unadj.) Rs10.0021.00 47.6%  
Dividend yield (eoy) %1.11.3 84.6%  
Book value per share (Unadj.) Rs301.8862.5 35.0%  
Shares outstanding (eoy) m110.55172.56 64.1%   
Bonus/Rights/Conversions IS--  
Price / Sales ratio x2.43.2 76.4%   
Avg P/E ratio x-42.921.5 -199.7%  
P/CF ratio (eoy) x-125.916.5 -763.9%  
Price / Book Value ratio x2.91.8 160.8%  
Dividend payout %-48.928.9 -169.0%   
Avg Mkt Cap Rs m97,063269,194 36.1%   
No. of employees `0006.84.0 168.7%   
Total wages/salary Rs m9,66517,939 53.9%   
Avg. sales/employee Rs Th5,931.821,190.3 28.0%   
Avg. wages/employee Rs Th1,428.14,470.1 31.9%   
Avg. net profit/employee Rs Th-334.03,120.0 -10.7%   
INCOME DATA
Net Sales Rs m40,14685,037 47.2%  
Other income Rs m1,1432,338 48.9%   
Total revenues Rs m41,28987,374 47.3%   
Gross profit Rs m12834,991 0.4%  
Depreciation Rs m1,4893,817 39.0%   
Interest Rs m2,25320,310 11.1%   
Profit before tax Rs m-2,47213,202 -18.7%   
Minority Interest Rs m01,699 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-100 0.0%   
Tax Rs m-2112,281 -9.3%   
Profit after tax Rs m-2,26012,520 -18.1%  
Gross profit margin %0.341.1 0.8%  
Effective tax rate %8.517.3 49.4%   
Net profit margin %-5.614.7 -38.2%  
BALANCE SHEET DATA
Current assets Rs m46,16087,590 52.7%   
Current liabilities Rs m19,258185,578 10.4%   
Net working cap to sales %67.0-115.2 -58.2%  
Current ratio x2.40.5 507.8%  
Inventory Days Days10131 324.6%  
Debtors Days Days9448 197.8%  
Net fixed assets Rs m40,165108,523 37.0%   
Share capital Rs m553345 160.2%   
"Free" reserves Rs m32,814148,481 22.1%   
Net worth Rs m33,367148,826 22.4%   
Long term debt Rs m31,903144,957 22.0%   
Total assets Rs m89,687482,394 18.6%  
Interest coverage x-0.11.7 -5.9%   
Debt to equity ratio x1.01.0 98.2%  
Sales to assets ratio x0.40.2 253.9%   
Return on assets %06.8 -0.1%  
Return on equity %-6.88.4 -80.5%  
Return on capital %-0.312.0 -2.8%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m9,12115,001 60.8%   
Fx outflow Rs m2,1335,150 41.4%   
Net fx Rs m6,9889,851 70.9%   
CASH FLOW
From Operations Rs m-2,695-100,393 2.7%  
From Investments Rs m-6,863-24,202 28.4%  
From Financial Activity Rs m12,545135,705 9.2%  
Net Cashflow Rs m3,01011,110 27.1%  

Share Holding

Indian Promoters % 74.5 52.9 140.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 2.3 4.0 57.5%  
FIIs % 7.7 26.6 28.9%  
ADR/GDR % 0.1 0.0 -  
Free float % 15.4 16.5 93.3%  
Shareholders   67,757 93,274 72.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare WOCKHARDT LTD. With:   PFIZER  ABBOTT INDIA  PANACEA BIOTECH  DR. REDDYS LAB  GSK PHARMA  

Compare WOCKHARDT LTD. With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Global Stock Markets Rebound After Sharp Weekly Drop(RoundUp)

Global financial markets rallied this week and brushed aside a rise in global borrowing costs while the dollar hit its lowest level since 2014.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Here's What You Should Do in this Market Crash(The 5 Minute Wrapup)

Feb 6, 2018

The market correction has provided a golden opportunity to buy five high-quality safe stocks.

As the Market Corrects... It's Time to Buy More(Smart Contrarian)

Feb 5, 2018

The recent sell off in the stock market offers buying opportunity in some quality small caps.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

When Small is Not Always Beautiful(Chart Of The Day)

Feb 6, 2018

Big companies enjoying tax deductions and exemptions have an edge over the small companies.

What Should Mutual Fund Investors Do After LTCG Tax Norms(Outside View)

Feb 6, 2018

PersonalFN explain what investors should after LTCG tax norms.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

WOCKHARDT LTD. SHARE PRICE


Feb 16, 2018 (Close)

TRACK WOCKHARDT LTD.

  • Track your investment in WOCKHARDT LTD. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON WOCKHARDT LTD.

WOCKHARDT LTD. - STERLING BIOTECH COMPARISON

COMPARE WOCKHARDT LTD. WITH

MARKET STATS